Literature DB >> 27865626

Synergistic combinations of polymyxins.

Justin R Lenhard1, Roger L Nation2, Brian T Tsuji3.   

Abstract

The proliferation of extensively drug-resistant Gram-negative pathogens has necessitated the therapeutic use of colistin and polymyxin B. However, treatment failures with polymyxin monotherapies and the emergence of polymyxin resistance have catalysed the search for polymyxin combinations that synergistically kill polymyxin-susceptible and -resistant organisms. This mini-review examines recent (2011-2016) in vitro and in vivo studies that have attempted to identify synergistic polymyxin combinations against Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Clinical evidence for the use of combination regimens is also discussed.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter baumannii; Combinations; Klebsiella pneumoniae; Polymyxins; Pseudomonas aeruginosa; Synergy

Mesh：

Substances：

Year:  2016        PMID： 27865626      PMCID： PMC5237374          DOI： 10.1016/j.ijantimicag.2016.09.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  60 in total

1.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

2.  Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.

Authors:  Irene Galani; Konstantina Orlandou; Helen Moraitou; George Petrikkos; Maria Souli
Journal:  Int J Antimicrob Agents       Date:  2014-02-04       Impact factor: 5.283

3.  Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Rujipas Sirijatuphat; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

4.  Is there really no benefit to combination therapy with colistin?

Authors:  Jason M Pogue; Keith S Kaye
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09       Impact factor: 5.091

5.  Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Authors:  T Tängdén; R A Hickman; P Forsberg; P Lagerbäck; C G Giske; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

6.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

7.  Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.

Authors:  Nusaibah Abdul Rahim; Soon-Ee Cheah; Matthew D Johnson; Heidi Yu; Hanna E Sidjabat; John Boyce; Mark S Butler; Matthew A Cooper; Jing Fu; David L Paterson; Roger L Nation; Phillip J Bergen; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-05-28       Impact factor: 5.790

8.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

9.  Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

Authors:  A Batirel; I I Balkan; O Karabay; C Agalar; S Akalin; O Alici; E Alp; F A Altay; N Altin; F Arslan; T Aslan; N Bekiroglu; S Cesur; A D Celik; M Dogan; B Durdu; F Duygu; A Engin; D O Engin; I Gonen; E Guclu; T Guven; C A Hatipoglu; S Hosoglu; M K Karahocagil; A U Kilic; B Ormen; D Ozdemir; S Ozer; N Oztoprak; N Sezak; V Turhan; N Turker; H Yilmaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-15       Impact factor: 3.267

10.  In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  Mao Hagihara; Seth T Housman; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191
View more
  26 in total

Review 1.  Improving therapy of severe infections through drug repurposing of synergistic combinations.

Authors:  Yu-Shan Cheng; Peter R Williamson; Wei Zheng
Journal:  Curr Opin Pharmacol       Date:  2019-08-24       Impact factor: 5.547

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

3.  Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against Klebsiella pneumoniae.

Authors:  Rong Wang; Shuang Hou; Xiaojing Dong; Daijie Chen; Lei Shao; Liujia Qian; Zhong Li; Xiaoyong Xu
Journal:  Medchemcomm       Date:  2017-09-14       Impact factor: 3.597

Review 4.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

5.  Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells.

Authors:  Cristina Brunati; Thomas T Thomsen; Eleonora Gaspari; Sonia Maffioli; Margherita Sosio; Daniela Jabes; Anders Løbner-Olesen; Stefano Donadio
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

Review 6.  Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria.

Authors:  Lucie Peyclit; Sophie Alexandra Baron; Jean-Marc Rolain
Journal:  Front Cell Infect Microbiol       Date:  2019-06-11       Impact factor: 5.293

7.  Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.

Authors:  Gabriel Torrens; Isabel M Barceló; Marcelo Pérez-Gallego; Maria Escobar-Salom; Sara Tur-Gracia; Marta Munar-Bestard; María Del Mar González-Nicolau; Yoandy José Cabrera-Venegas; Estefany Nayarith Rigo-Rumbos; Gabriel Cabot; Carla López-Causapé; Estrella Rojo-Molinero; Antonio Oliver; Carlos Juan
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 8.  Multitarget Approaches against Multiresistant Superbugs.

Authors:  Declan Alan Gray; Michaela Wenzel
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

9.  Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments.

Authors:  Anna Olsson; Pikkei Wistrand-Yuen; Elisabet I Nielsen; Lena E Friberg; Linus Sandegren; Pernilla Lagerbäck; Thomas Tängdén
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 10.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.